Indication approvals and marketing authorizations for anti-TNF drugs by... | Download Table
Biosimilar medicine fact sheet – infliximab | Australian Government Department of Health and Aged Care
Infliximab (Remicade) Startup sheet | IBD Clinic
The US Biosimilar Market Where Is It Today And Where Is It Going
J&J braces for biosim attack after losing last-ditch Remicade patent fight | Fierce Pharma
REMICADE® (infliximab) Overview | Janssen CarePath for Healthcare Professionals
Ask the Expert—Are biosimilars as effective as their biologic counterparts?
Samsung Bioepis and Merck Launch Renflexis® in the U.S. | Biosimilars Law Bulletin
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial - The Lancet Gastroenterology & Hepatology
REMICADE 100mg - Buy online in OGOmed
Subcutaneous Infliximab In The US Defining CT-P13 SC's Competitive Edge
Fuld & Company | Biosimilar Infliximab - What's All the Excitement About? - Fuld & Co
AVSOLA®(infliximab-axxq)'s Totality of Evidence
REMICADE® (infliximab) Overview | Janssen CarePath for Healthcare Professionals
Biosimilar strategy for infliximab by MedDrive™ includes the reference drug - Prime Therapeutics LLC
U.S. Biosimilar Launches Accelerate with Five Launches in Q4 2019 and early 2020 | Biosimilars Law Bulletin
g30513mm01i001.jpg
Remicade® (infliximab): 20 years of contributions to science and m | BTT
761072Orig1s000
U.S., European Biosimilar Approval Activity in 2017
These highlights do not include all the information needed to use REMICADE® safely and effectively. See full prescribing information for REMICADE. REMICADE (infliximab) for injection, for intravenous use Initial U.S. Approval: 1998
